JP2012106989A5 - - Google Patents

Download PDF

Info

Publication number
JP2012106989A5
JP2012106989A5 JP2011222017A JP2011222017A JP2012106989A5 JP 2012106989 A5 JP2012106989 A5 JP 2012106989A5 JP 2011222017 A JP2011222017 A JP 2011222017A JP 2011222017 A JP2011222017 A JP 2011222017A JP 2012106989 A5 JP2012106989 A5 JP 2012106989A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
hybridoma
composition according
atcc accession
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011222017A
Other languages
Japanese (ja)
Other versions
JP5583648B2 (en
JP2012106989A (en
Filing date
Publication date
Priority claimed from US10/813,336 external-priority patent/US7235376B2/en
Application filed filed Critical
Publication of JP2012106989A publication Critical patent/JP2012106989A/en
Publication of JP2012106989A5 publication Critical patent/JP2012106989A5/ja
Application granted granted Critical
Publication of JP5583648B2 publication Critical patent/JP5583648B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Claims (5)

ハイブリドーマ４００−１（ＡＴＣＣアクセッション番号ＰＴＡ−５８８９）、ハイブリドーマ４００−２（ＡＴＣＣアクセッション番号ＰＴＡ−５８９０）、ハイブリドーマ４００−３（ＡＴＣＣアクセッション番号ＰＴＡ−５８９１）及びハイブリドーマ４００−４（ＡＴＣＣアクセッション番号ＰＴＡ−５８９２）によって産生されるモノクローナル抗体と薬学的に許容される担体とを含む、癌治療用医薬組成物。   Hybridoma 400-1 (ATCC accession number PTA-5589), hybridoma 400-2 (ATCC accession number PTA-5890), hybridoma 400-3 (ATCC accession number PTA-5589) and hybridoma 400-4 (ATCC accession) No. PTA-5892), a pharmaceutical composition for treating cancer, comprising a monoclonal antibody produced by the method and a pharmaceutically acceptable carrier. 前記癌が膵癌である、請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, wherein the cancer is pancreatic cancer. 前記癌が胃癌である、請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, wherein the cancer is gastric cancer. 前記癌が大腸癌である、請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, wherein the cancer is colorectal cancer. 前記モノクローナル抗体がヒト化されている、請求項１〜４のいずれか一項に記載の医薬組成物。   The pharmaceutical composition according to any one of claims 1 to 4, wherein the monoclonal antibody is humanized.
JP2011222017A 2004-03-29 2011-10-06 Monoclonal antibody against gastrin hormone Expired - Lifetime JP5583648B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55775904P 2004-03-29 2004-03-29
US60/557,759 2004-03-29
US10/813,336 2004-03-29
US10/813,336 US7235376B2 (en) 2003-03-28 2004-03-29 Gastrin hormone immunoassays

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007506474A Division JP5576592B2 (en) 2004-03-29 2005-03-29 Monoclonal antibody against gastrin hormone

Publications (3)

Publication Number Publication Date
JP2012106989A JP2012106989A (en) 2012-06-07
JP2012106989A5 true JP2012106989A5 (en) 2013-01-31
JP5583648B2 JP5583648B2 (en) 2014-09-03

Family

ID=38252205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011222017A Expired - Lifetime JP5583648B2 (en) 2004-03-29 2011-10-06 Monoclonal antibody against gastrin hormone

Country Status (2)

Country Link
JP (1) JP5583648B2 (en)
CN (1) CN1997669A (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3624841A4 (en) * 2017-06-15 2021-01-27 Cancer Advances, Inc., COMPOSITIONS AND METHODS OF INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
CN109762058A (en) * 2018-11-20 2019-05-17 杭州贤至生物科技有限公司 A kind of preparation recombinating G-17 albumen and its monoclonal antibody
CN111150842B (en) * 2019-12-31 2023-09-05 优锐生物医药科技(深圳)有限公司 Active immune regulation microparticles for neutralizing gastrin and its preparation method and application
CN112062846A (en) * 2020-04-27 2020-12-11 杭州博茵生物技术有限公司 G-17 monoclonal antibody and application thereof
CN115639360B (en) * 2021-07-19 2025-05-13 武汉市朗典精医生物科技有限公司 Preparation of progastrin (PG80) antibodies and establishment of CLIA PG80 detection kit
CN114924016B (en) * 2022-04-28 2024-03-08 中国医学科学院北京协和医院 Method for simultaneously detecting sulfated and unsulfated gastrin G17 and its detection kit
WO2026022157A1 (en) * 2024-07-22 2026-01-29 Roche Diagnostics Gmbh Anti-gastrin antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2063912T3 (en) * 1989-01-24 1995-01-16 Aphton Corp IMMUNOGENIC COMPOSITIONS AGAINST GASTRINE PEPTIDES.

Similar Documents

Publication Publication Date Title
JP2012106989A5 (en)
LTPA2017040I1 (en) Antibodies to CD38 antigen for the treatment of multiple myeloma
JP2014205674A5 (en)
JP2013198490A5 (en)
JP2014509837A5 (en)
JP2012116856A5 (en)
NZ602294A (en) Monoclonal antibodies against c-met
JP2016520514A5 (en)
JP2012121878A5 (en)
NZ602040A (en) Anti-lrp6 antibodies
IL184152A (en) Monoclonal antibodies against nkg2a, compositions comprising the same, uses thereof for the manufacture of medicaments, methods for their production and methods employing said antibodies
IL230564B1 (en) Inhibitory anti-factor xii/xiia monoclonal antibodies, methods of producing the same, pharmaceutical compositions containing the same and medical uses
JP2012034692A5 (en)
NZ604007A (en) Monoclonal antibodies against her2 epitope
IL212633A (en) Monoclonal antibody or antigen-binding fragment thereof, pharmaceutical compositions comprising the same and use thereof for the manufacture of medicaments for the treatment of cancer
JP2013173775A5 (en)
WO2013064701A3 (en) Specific antibodies and their isolation with anti-idiotypic antibodies
JP2017510661A5 (en)
JP2011157378A5 (en)
MX2020009700A (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use.
JP2013539454A5 (en)
JP2011517447A5 (en)
WO2013004076A8 (en) Agr2 blocking antibody and use thereof
JP2012518624A5 (en)
NZ604464A (en) Anti-vegf antibodies and uses thereof